# Safety and Tolerance Study of Grass Pollen-derived Peptides to Treat Allergic Rhinitis

> **NCT00813046** · PHASE1 · COMPLETED · sponsor: **BioTech Tools S.A.** · enrollment: 8 (actual)

## Conditions studied

- Seasonal Allergic Rhinoconjunctivitis

## Interventions

- **BIOLOGICAL:** gpASIT+TM

## Key facts

- **NCT ID:** NCT00813046
- **Lead sponsor:** BioTech Tools S.A.
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE1
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2008-12
- **Primary completion:** 2009-01
- **Final completion:** 2009-01
- **Target enrollment:** 8 (ACTUAL)
- **Last updated:** 2014-05-26


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT00813046

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT00813046, "Safety and Tolerance Study of Grass Pollen-derived Peptides to Treat Allergic Rhinitis". Retrieved via AI Analytics 2026-08-17 from https://api.ai-analytics.org/clinical/NCT00813046. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*